# A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years

> **NCT03962062** · PHASE1 · COMPLETED · sponsor: **Medicines Development for Global Health** · enrollment: 36 (actual)

## Conditions studied

- Onchocerciasis

## Interventions

- **DRUG:** Moxidectin

## Key facts

- **NCT ID:** NCT03962062
- **Lead sponsor:** Medicines Development for Global Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-29
- **Primary completion:** 2022-05-30
- **Final completion:** 2022-09-28
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03962062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03962062, "A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03962062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*